Further, our clinical studies have reported that humans with Chronic Granulomatous Disease (CGD), due to mutations in the gp91phox subunit and no residual NADPH oxidase 2 activity, have reduced incidence of diabetes as compared to that in the general population (56). The gene discussed is CYBB; the disease is chronic granulomatous disease.